<DOC>
	<DOCNO>NCT00063687</DOCNO>
	<brief_summary>The OPT-CHF ( OxyPurinol Therapy CHF ) study design demonstrate efficacy safety oral oxypurinol vs. placebo randomize , double-blind , twenty-four week trial 400 patient 50 center . Measures clinical efficacy ( NYHA class Patient Global Assessment ) well clinical outcome ( e.g. , death , worsen heart failure , hospitalization ) assess composite endpoint trial .</brief_summary>
	<brief_title>Oxypurinol Compared With Placebo Class III-IV NYHA Congestive Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Oxypurinol</mesh_term>
	<criteria>Inclusion criterion 1885 year old , Stable NYHA Class IIIIV Hospitalization ER visit past 18 month worsen Heart Failure ( addition new heart failure medication add regimen due lack stability current regimen . EF = &lt; 40 % Exclusion criteria Any condition ( CHF ) could limit exercise Any concurrent disease likely limit life expectancy . Participation another clinical trial Primary valvular disease , active myocarditis , obstructive restrictive cardiomyopathy Heart Attack , Stroke , Unstable Angina Cardiac surgery within previous 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2003</verification_date>
</DOC>